Prior treatment with vitamin K₂ significantly improves the efficacy of risedronate

Y. Matsumoto · Y. Mikuni-Takagaki · Y. Kozai · K. Miyagawa · K. Naruse · H. Wakao · R. Kawamata · I. Kashima · T. Sakurai

Received: 9 October 2008 / Accepted: 21 January 2009 / Published online: 12 March 2009 © The Author(s) 2009. This article is published with open access at Springerlink.com

Abstract

Summary Prior 8-week treatment with menatetrenone, MK-4, followed by 8-week risedronate prevented the shortcomings of individual drugs and significantly increased the strength of ovariectomized ICR mouse femur compared to the ovariectomized (OVX) controls. Neither MK-4 following risedronate nor the concomitant administration may be recommended because they brought the least beneficial effect.

Introduction The objective of this study was to determine the best combinatory administration of risedronate at 0.25 mg/kg/day (R) with vitamin K₂ at approximately 100 μg MK-4/kg/day (K) to improve strength of osteoporotic mouse bone.

Methods Thirteen-week-old ICR mice, ovariectomized at 9-week, were treated for 8 weeks with R, K, or R plus K (R/K), and then, either the treatment was withdrawn (WO) or switched to K or R in the case of R and K. After another 8 weeks, the mice were killed, and mechanical tests and analyses of femur properties by peripheral quantitative computed tomography, microfocus X-ray tube computed tomography, and confocal laser Raman microspectroscopy were carried out.

Results The K to R femur turned out superior in parameters tested such as material properties, bone mineral density, BMC, trabecular structure, and geometry of the cortex. The increased cross-sectional moment of inertia, which occurred after K withdrawal, was prevented by risedronate in K to R. In addition to K to R, some properties of R to WO diaphysis and K to WO epiphysis were significantly better than OVX controls.

Conclusion Prior treatment with MK-4 followed by risedronate significantly increased femur strength in comparison to the OVX controls.

Keywords Bisphosphonate · Quality of bone · Raman spectroscopy · Risedronate · Sequential administration · Vitamin K₂

Introduction

Bisphosphonate is one of the most effective drugs currently available for suppressing bone resorption. Naturally, combination therapies with other antiresorptive or formative agents have been investigated: PTH [1–3], vitamin D [2, 4], estrogen [5–7], and other agents [8]. Risedronate, a pyridinyl (amino) bisphosphonate, significantly reduces
the risk of hip fracture among elderly women with confirmed osteoporosis and if combined with estrogen or raloxifene, produces greater gains in bone mass in comparison to single-agent treatment [9]. Oral administration or intake from food of vitamin K$_2$, on the other hand, has been shown to prevent the occurrence of fractures in Japanese women [10, 11] and was reported to prevent bone loss partly through the improved bone formation in animal studies [12]. It was also reported that vitamin K$_2$ (MK-4) inhibited bone resorption [13]. A more recent cellular study reported that the osteoprotective action of vitamin K$_2$ is through steroid and xenobiotic receptor (SXR)/pregnane X receptor (PXR)-modulated Msx2 gene transcription [14]. Such an entirely different pharmacological action of vitamin K$_2$ from other drugs would make it worth studying combinatory administration with bisphosphonate. Limited reports of trabecular bone implied that the combined treatment is more efficacious in osteoporotic rats [15, 16], while others have reported otherwise [17, 18]. Therefore, the efficacy of their combinatory use was further investigated in ovariec
tomized (OVX) ICR mice to clarify the effect on the cortical bone and strength. We tried to separate the effect of vitamin K$_2$ on matrix from that on mineral and to compare with the effect of risedronate by lowering the experimental vitamin K$_2$ intake level to ~100μg MK-4/kg/day, which is at the dietary level.

Materials and methods

Experimental animals

The Animal Care Committee of Kanagawa Dental College approved the entire experimental protocol. Nine-week-old ICR mice were purchased from Japan Clea (Tokyo, Japan). All animals were kept under local vivarium conditions (temperature 23.3°C, humidity 55% and a 12-h on/off light cycle).

Sixteen-week-treatment experiment

Fifty-nine, 9-week-old, female ICR mice were either ovariec
tomized ($n=43$) or sham-operated ($n=8$). After a month, during which all mice were fed with conventional rodent food pellets, the ovariec
tomized mice were divided into six groups. In addition to the OVX group ($n=8$), five groups ($n=7$) received medication, which was switched at the 8-week midpoint. In the K to R group, mice were treated with MK-4 for 8 weeks and then with risedronate for eight more weeks. R to K mice were treated with risedronate first and then with vitamin K$_2$. K to WO, R to WO, and R/K to WO mice received either vitamin K$_2$, risedronate, or both for 8 weeks, and then the drug(s) was withdrawn. Except in the OVX groups during K and R/K period, which received pellets containing 50μg/100 g vitamin K$_2$ (MK-4), all animals received the conventional rodent food. Both the conventional rodent pellets (CE-2) and the vitamin K$_2$ pellets were prepared by Japan Clea with MK-4 kindly provided by Eizai (Tokyo, Japan). Calculated from the average 6 to 7 g a day consumption of the ration, the pellets were prepared so that the animals received ~100μg MK-4/kg/day, which is at a dietary level. During the R or R/K period, mice received 0.25 mg/kg of daily oral risedronate after 2-h fasting. They were fed after another 2-h fasting. The femurs were excised from mice euthanized after the 16-week therapeutic period and were preserved at −80°C for microfocused X-ray computed tomography (micro-CT) and peripheral quantitative computed tomography (pQCT) analyses and confocal Raman spectroscopy.

Eight-week-midpoint experiment

To examine femurs at the 8-week midpoint, total of 42 ICR mice were treated under similar conditions to those of the 16-week experimental animals. They underwent either sham surgery ($n=9$) or an ovariectomy ($n=33$). OVX groups include control OVX (OVX, $n=9$), OVX treated with risedronate (OVX-R, $n=8$) or vitamin K$_2$ (OVX-K, $n=8$), and the concomitant administration (OVX-R/K, $n=8$).

Microfocused X-ray computed tomography

Using MCT-CB 130F (Hitachi Medico, Tokyo, Japan), three-dimensional imaging data of the distal epiphyseal region of the femur, between 1.5 to 2.75 mm proximal to the growth plate, were obtained. The spatial resolution was set to 7μm with the voxel size of 17.8 × 17.8 × 17.8 (μm), and the tube voltage and current were 60 kV and 100μA, respectively. The resolution was set to medium (200 projections each), and slice thickness and increment were set to 20μm. A morphological analysis was carried out using TRI 3D BONE (Ratoc System Engineering, Tokyo) for such parameters as BV (mm$^3$), bone volume; BS (mm$^3$), bone surface; BV/TV (%), bone volume fraction; Tb.Th (μm), trabecular thickness; Tb.N (1/mm), trabecular number; Tb.Sp (μm), trabecular separation; Tb.Spacing (μm), trabecular Space; FD, fractal dimension [19]; and structural model index, SMI [20].

Peripheral quantitative computed tomography

The distal metaphysis, 1.4 mm proximal to the growth plate and mid-diaphysis of femurs (5 mm proximal to the midpoint), was scanned by a Research SA+ pQCT model (Norland Stratec, Berkenfeld, Germany) with a tube voltage of 50 kV and a tube current of 550μA using a voxel size of
80 × 80 × 46 (µm). The cortical bone was defined as the area of bone mineral density (BMD) >690 mg/mm³, while a threshold of 395 mg/mm³ at the contour mode 1 was set to define trabecular bone in the bone marrow. Total BMD (mg/cm³) and the content, BMC (mg/mm), were presented as metaphyseal mineral properties. In addition, the cortical thickness (CTh), cross-sectional moment of inertia (CSMI), and polar stress/strain index (pSSI), an index of strength [21], were calculated.

Mechanical properties of femurs

The bone strength of the femoral diaphysis and distal epiphysis was evaluated using three-point breaking tests and compression tests using a MZ-500 s device (Maruto, Tokyo, Japan). The crosshead speed in the three-point breaking test and the compression test was 10 and 1.0 mm/min, respectively. In the latter, the distal epiphysis, approximately 3.0 mm thick, was compressed to 1.5 mm. The ultimate load (UL) and stiffness (s) were determined from the load–displacement curve and were converted to the material properties. Ultimate stress (US) was calculated by using the equation US = (UL×d×L)/(8×CSMI), where d is the diameter at midshaft, and L is the support span at the bottom (10 mm). The elastic modulus, E, was calculated by using the equation E = (s×L³)/(48×CSMI).

Confocal Raman spectroscopic measurements

Confocal laser Raman microspectroscopy was used to examine the composition and relative amounts of the mineral and matrix produced in the tibia. Raman spectroscopy is particularly useful for bone analysis because it probes the molecular and ionic vibrations of the mineral and matrix component in unprocessed preparations that preserve these components. The innate, prominent vibrations were measured as described by Tarnowski et al. [22]. Crystallinity was determined using the method reported by Yerramshetty et al. [23] as the inverse of the width of the phosphate symmetric stretch band (PO₄³⁻ ν₁ at 959 cm⁻¹) at half the maximum intensity value. A Nicolet Almega XR Dispersive Raman microscope system equipped with the OMNIC Almega™ imaging software program (Thermo Fisher Scientific, MA, USA), which enable to map a small area less than 1 µm² on the bony microsurface of the cortical bone on the video microscope stage control. A high brightness, low-intensity laser operating at 780 nm was used as the excitation source with a laser power of 35 mW. Each spectrum is the sum of ten 10-s measurements. The spectral resolution of the Almega XR under the conditions used was 3.85 cm⁻¹. For each femur, one averaged Raman image was acquired in the middle of the anterior cortical bone by the ten 10-s measurements.

Statistical analysis

All data values were expressed as the means±standard deviation (SD). Unless otherwise mentioned, the group means for each parameter were determined for the 8-week mid-point experimental results and compared using a one-way analysis of variance (ANOVA), with the post hoc Tukey–Kramer test.
Dunnett’s multiple comparisons test was used for 16-week treatment groups with the OVX group as a reference. The probability values of $p < 0.05$ were considered to be statistically significant for all the comparisons. The Stat View software package (Stat View 5.0; Abacus Concepts, Berkeley, CA, USA) was used for all analyses.

**Results**

**Body weight and length of femur**

The body weight, which was 33.6 ± 2.1 at the ovariectomy (~4 weeks), ranged from 37.4 ± 2.1 to 40.3 ± 3.0 g at 0 week in the sham and OVX groups. At 8 and 16 weeks, the range in all groups was between 40.9 ± 2.7 and 44.3 ± 4.3 g and 43.6 ± 7.5 and 49.4 ± 7.0 g, respectively. The length of the femur at the time they were killed ranged between 17.5 ± 0.6 and 17.8 ± 0.4 mm. Neither body weight nor the length of femur showed any significant difference in any of the treatment groups compared to the OVX or sham group (data not shown). While the body weight in OVX groups tended to be larger at 0 and 8 weeks, no significant effect was detected (data not shown). No intergroup difference was detected either (data not shown).

**Mechanical tests of femurs after the 16-week treatments**

As shown in the Fig. 1, the bending strength of the femoral diaphysis (top panels) and the compressive strength of the...
femoral distal metaphysis (bottom panels) were tested. In comparison to the OVX bone, a significant difference was detected in the sham bone as revealed by the elastic modulus as well as the ultimate stress values. The deficit in the OVX was restored in K to R in all four parameters, R to WO in the ultimate stress by three-point bending test, and K to WO in the ultimate stress by compression test.

Changes in the cortical bone quality

Right panels in Fig. 2 show the results at the 16-week termination. The OVX control group showed a significant decrease in the cortical BMD and BMC as well as thinning of the cortical thickness and a decreased pSSI in comparison to the sham group. The final 16-week cortical BMD, BMC (Fig. 2a) and thickness (Fig. 2b) did not significantly change by any treatment from the 8-week stage except in the K to R cortical BMC. Among the treated groups, only the K to R group showed significantly higher values (lower in CSMI) than the OVX controls in all the parameters presented. Unless followed by risedronate, treatment by MK-4 did not significantly increase mineral content or density neither in diaphysis nor in metaphysis. Only in the K to R group was CSMI significantly smaller than the 16-week OVX control. The K to R femur alone also raised the pSSI value, the calculated index of strength, to the levels of the sham group during the later 8-week treatment by risedronate (Fig. 2b). When we compare CSMI values in the 16-week treatment groups to their respective 8-week values by the Student's t test, many groups, including sham, OVX, R to K, R to WO, and K to WO, significantly increased the values during the later 8-week treatment. In the R/K to WO group, only the K to R group showed significantly higher values than the OVX-R/K 8-week midpoint. The R to WO group but not R/K to WO was also distinct showing significantly higher values than the OVX control in both cortical BMC and thickness.

Analysis of Raman spectra (Fig. 3) revealed that the resolvable mineral factor was of a carbonated apatite almost identical to what was reported by Tarnowski et al. [22] \((\text{PO}_4^{3-} \nu_1, 959 \text{ cm}^{-1}; \text{PO}_4^{3-} \nu_4, 580 \text{ cm}^{-1}; \text{CO}_3^{2-} \nu_1, 1,072 \text{ cm}^{-1})\), and the matrix factor was of a collagenous protein (amide I, 1,666 cm\(^{-1}\); amide III, 1,242 and 1,269 cm\(^{-1}\); \(\text{CH}_2\) wag, 1,450 cm\(^{-1}\); hydroxyproline, 855 and 878 cm\(^{-1}\); proline, 919 cm\(^{-1}\); \(\text{HPO}_4^{2-}\), 1,005 cm\(^{-1}\); data not shown). While mineral properties such as the crystallinity were unchanged in all groups throughout the
16-week experiment, the cortical mineral to matrix ratio measured by PO$_4^{3-}$/ν1/amide I was significantly lower, and Hypro/Pro ratio was significantly higher only in OVX-K at 8 weeks than the OVX controls. At 16 weeks, the PO$_4^{3-}$/amide I ratio significantly increased in K to WO alone, revealing the decreased collagenous matrix by the MK-4 withdrawal. Hypro/Pro ratio was all similar at 16 weeks.

Changes in the trabecular architecture

The effects of K to R on the distal metaphyseal (Fig. 2a) and the distal epiphyseal trabeculi (Table 2 and Fig. 4) were also quite significant. In Tables 1 and 2, the structural parameters by micro-CT analysis are summarized. In comparison to the OVX controls, sham group showed significant differences in the BV, BS, BV/TV, Tb.Th, Tb.N, and FD (larger) and Tb.Sp (smaller) at 8 weeks. All three 8-week treatment groups, OVX-R, K, and R/K, showed significant difference from the OVX group in many parameters (Table 1). Of note, the concomitant administration, OVX-R/K, was no more effective than the OVX-K or OVX-R monotherapy. The effect of 16-week treatment with MK-4 and/or risedronate was as follows. Both K to R and K to WO groups showed significantly better BV, BS, BV/TV, Tb.N, and Tb.Sp values in comparison to the OVX group ($p < 0.01$ in K to R). Figure 2a also shows that K to R and R to K groups were higher in the metaphyseal total BMD and BMC, while BMC values were also higher in the R to WO and R/K to WO. Risedronate raised metaphyseal total BMC by more than 50% in K to R during the later 8 weeks. On the other hand, the R to WO and R/K to WO significantly lowered Tb.Th in comparison to the OVX control group (Table 2). In contrast to the MK-4 withdrawal, R to WO and R/K to WO lowered other trabecular structural parameters as well to the levels of OVX controls (Table 2). Figure 4 represents reconstructed 3-D images at 16 weeks of the distal epiphyseal region. The trabecular architecture looked poor in the OVX control and R/K to WO groups.

Discussion

Generally, drugs targeting different functions are combined for multidrug therapy with the expectation of complementary action. For vitamin K, however, even the efficacy by itself is still controversial. Earlier, low concentrations of
circulating vitamin K have been associated with bone fractures [24] and with low bone mineral density [25]. The undercarboxylated osteocalcin was associated with fracture risk [26, 27], and its reduction by the vitamin K intake was reported without the effect on BMD [28]. Furthermore, a vitamin K intake level of less than 109 μg/day has been reported to be a risk factor for hip fracture in women [29]. Shiraki et al. treated postmenopausal patients with 45 mg/day MK-4 and reduced the new fractures to one third. Their lumbar BMD was found to be significantly higher than that observed in the control women [10]. In a more recent study, the combination of alendronate with 45 mg/day MK-4 was reported to be superior to alendronate monotherapy in decreasing undercarboxylated osteocalcin, increasing femoral neck BMD and decreasing the urinary deoxypyridinoline [30]. In the animal studies, a much higher dosage of 30–50 mg MK-4/kg/day has been used, thus resulting in a significantly higher mineral content in cortical bone without bisphosphonate [31]. However, the results are inconsistent among different animals or strains [16–18, 32–34]. In the present study, we did not observe significant increase in BMD or BMC at the lower level of ~100 μg/kg/day unless MK-4 was followed by risedronate.

Vitamin K2 has been known to be essential for the γ-carboxylation of osteocalcin [35]. Therefore, the function was once assumed through activating osteoblasts and

| Table 1 Three-dimensional structural parameters of epiphysial trabecular bone at 8 weeks |
|---------------------------------------------|-------------|-----------------|-------------|-------------|-------------|-------------|-------------|
| BV (mm³) | BS (mm²) | BV/TV(%) | Tb.Th (μm) | Tb.N (/mm) | Tb.Sp (μm) | FD | SMI |
| Sham | 0.69±0.15a | 24.7±5.3a | 30.5±5.8b | 54.7±3.2b | 5.5±0.9b | 137.3±75.1a | 2.3±0.0b | 2.7±0.2 |
| OVX control | 0.27±0.05 | 11.8±1.8 | 14.1±4.7 | 45.2±1.3 | 3.1±0.5 | 334.7±26.0 | 2.1±0.0 | 2.7±0.2 |
| OVX-K | 0.67±0.05a | 27.3±1.7a | 29.5±1.8a | 48.2±0.9 | 5.8±0.2a | 127.6±24.5a | 2.3±0.0b | 3.1±0.2 |
| OVX-R | 0.56±0.01a | 22.8±1.5a | 22.7±1.8 | 47.7±1.2 | 4.6±0.5 | 190.9±19.1b | 2.2±0.0 | 3.2±0.3bc |
| OVX-R/K | 0.65±0.06a | 24.3±1.7a | 25.9±1.8b | 50.6±0.9 | 4.8±0.2 | 165.7±24.9b | 2.2±0.0 | 3.4±0.3bc |

Data are expressed as means±SD. Group comparisons were performed by analysis of variance (ANOVA) followed by Tukey–Kramer test. No significant difference was detected between OVX groups

*p < 0.01 vs OVX controls

b p < 0.05 vs OVX controls

c p < 0.05 vs sham
leading them to enhanced mineralization [36]. The mice genetically deficient for osteocalcin, however, exhibited the gain in bone mass instead of loss [37], suggesting that the osteoprotective action of vitamin K is mediated by some other pathways. Recent reports showed that vitamin K2 activates osteoblastic transcription of extracellular matrix-related genes [38] through steroid and xenobiotic receptor (SXR)/pregnane X receptor (PXR)-mediated Msx2 gene transcription in cooperation with the estrogen-bound ERα [14].

According to the findings of our 8-week administration, only the MK-4 monotherapy at the dietary level resulted in cortical bone matrix formation and maturation without significant increase in BMD or BMC. It was shown that vitamin K2 not only stimulates cortical bone matrix formation but also accelerates proline hydroxylation, which is a prerequisite for collagen cross-linking to achieve a mature collagenous matrix. Whether the enzymes involved in these processes are the target of vitamin K2 or not is yet to be resolved. In addition, MK-4 alone provided significant effect in most of the structural parameters of femoral trabecular bone. On the other hand, risedronate, at 0.25 mg/kg/day, was certainly effective, alone or in combination with MK-4, in femoral cortical BMD, BMC, and some trabecular structural parameters in the 8-week treatment. Of note, however, the 8-week concomitant administration was no more effective than each effective monotherapy. This led us to investigate the sequential administration of the two drugs with the same total dosage. The resulting final mechanical properties at 16 weeks were significantly better than the OVX controls only in K to R group. Despite of beneficial effects of 8-week MK-4 pretreatment on the cortical bone matrix, enhanced degradation of collagen seems to occur if the MK-4 is discontinued. In other words, the elevated 16-week mineral/matrix ratio in K to WO is distinct from the lowest 8-week midpoint ratio in the OVX-K. In contrast, the K to R group retained a much lower mineral/matrix ratio at 16 weeks. Since the K to WO mineral value, the numerator, is lower than the K to R value judged from the cortical BMD, the higher mineral/matrix ratio in K to WO was derived from the denominator, the smaller matrix value. It suggests either the collagen degradation or the decreased synthesis after the MK-4 withdrawal. An elevated serum CTx value was observed in K to WO in the later 8 weeks (data not shown). During the later 8-week treatment in K to R, risedronate clearly prevented the increase in CSMI, which occurred in K to WO. The lack of such prevention as well as the lack of other beneficial effects found in K to R cortex, such as the higher/larger BMD, BMC, and thickness, would explain why no significant effect was detectable in K to WO by the three-point bending test. In the MK-4 treated pre-OVX rats, Iwamoto et al. reported the elevated eroded surface as well as the bone formation rate that remained high after the MK-4 withdrawal [16]. The cellular mechanisms of the elevated collagen degradation therefore have to be confirmed in the future.

In the compression test, the ultimate stress parameter of K to WO as well as of K to R was significantly larger than the OVX control. This result was supported by the significantly better parameters of the trabecular structure in K to WO such as BV, BS, BV/TV, Tb.N, and Tb.Sp in comparison to the OVX controls. No such benefit was observed in R to WO and R/K to WO. The difference in the effect of MK-4 withdrawal on cortical bone and trabecular bone may be related to the distinct distribution of ERα vs. ERβ [39] or the different ERα signaling pathways [40], on the assumption that vitamin K and estrogen via the ERα cooperatively promote the osteoblast function through the Msx2 gene induction [14].

Concomitant administration of risedronate and MK-4 is probably not recommended because R/K to WO was generally not beneficial except in the metaphyseal total BMC. In addition, R to WO but not R/K to WO cortical bone matrix formation and maturation without significant increase in BMD or BMC. It was shown that vitamin K2 not only stimulates cortical bone matrix formation but also accelerates proline hydroxylation, which is a prerequisite for collagen cross-linking to achieve a mature collagenous matrix. Whether the enzymes involved in these processes are the target of vitamin K2 or not is yet to be resolved. In addition, MK-4 alone provided significant effect in most of the structural parameters of femoral trabecular bone. On the other hand, risedronate, at 0.25 mg/kg/day, was certainly effective, alone or in combination with MK-4, in femoral cortical BMD, BMC, and some trabecular structural parameters in the 8-week treatment. Of note, however, the 8-week concomitant administration was no more effective than each effective monotherapy. This led us to investigate the sequential administration of the two drugs with the same total dosage. The resulting final mechanical properties at 16 weeks were significantly better than the OVX controls only in K to R group. Despite of beneficial effects of 8-week MK-4 pretreatment on the cortical bone matrix, enhanced degradation of collagen seems to occur if the MK-4 is discontinued. In other words, the elevated 16-week mineral/matrix ratio in K to WO is distinct from the lowest 8-week midpoint ratio in the OVX-K. In contrast, the K to R

### Table 2

Three-dimensional structural parameters of epiphyseal trabecular bone at 16 weeks

|          | BV (mm³) | BS (mm²) | BV/TV (%) | Tb.Th (μm) | Tb.N (/mm) | Tb.Sp (μm) | FD    | SMI  |
|----------|----------|----------|------------|------------|------------|------------|-------|------|
| Sham     | 0.14±0.05b | 8.0±3.2b  | 6.3±2.0b   | 35.4±2.0   | 1.8±0.6b   | 602±273b   | 1.9±0.0 | 2.6±0.2 |
| Control  | 0.08±0.03 | 5.1±1.6   | 3.6±1.0    | 32.0±3.1   | 1.1±0.3    | 944±279    | 1.8±0.1 | 2.7±0.1 |
| K to R   | 0.22±0.06a | 12.9±2.7a | 9.8±2.4a   | 34.2±3.9   | 2.6±0.5a   | 369±100a   | 2.0±0.1 | 2.5±0.1 |
| K to WO  | 0.15±0.06b | 9.8±3.8b  | 6.7±2.6b   | 31.0±3.8   | 2.1±0.8b   | 536±291b   | 1.9±0.1 | 2.5±0.1 |
| R to K   | 0.14±0.03b | 7.8±1.9   | 6.0±1.4    | 33.6±3.5   | 1.7±0.4    | 733±376    | 1.9±0.1 | 2.6±0.1 |
| R to WO  | 0.07±0.03  | 5.6±2.3   | 3.5±1.0    | 26.0±1.8b  | 1.3±0.3    | 771±225    | 1.7±0.1 | 2.8±0.1 |
| R/K to WO| 0.10±0.04  | 6.8±2.7   | 3.9±1.7    | 27.7±2.3b  | 1.4±0.6    | 828±397    | 1.8±0.1 | 2.8±0.1 |

Data are expressed as means±SD. Group comparisons were performed by analysis of variance (ANOVA) followed by Dunnett’s test vs. OVX controls

\( a_p < 0.01 \)

\( b_p < 0.05 \)
thickness and BMC are significantly higher at 16 weeks than the OVX control, resulting in the increased ultimate stress only in R to WO. Since OVX-R and OVX-RK at 8 weeks exhibited similar cortical thickness and BMC values, the negative effect of RK withdrawal is apparent. The continuous 16-week administration of risedronate and MK-4 (R/K to R/K) was not beneficial in any parameters tested, including the metaphyseal total BMC (data not shown). Although R to K also showed a significantly positive effect in metaphyseal total BMD and BMC, it is probably not recommended to follow R by K because none of the benefits available in the cortex of R to WO was seen in R to K. In conclusion, prior 8-week treatment with MK-4 followed by the 8-week risedronate prevented the shortcomings of individual drugs and significantly increased femur strength of ICR mice compared to the OVX controls.

Acknowledgments We are grateful to Takami Furuhama for her valuable technical assistance. This investigation was supported in part by grants-in-aid from the Ministry of Science, Education and Culture of Japan to YM-T and IK.

Conflicts of interest None.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MH (1995) The anabolic effect of human PTH (1–34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate— is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16(6):603–610

2. Boyce RW, Paddock CL, Franks AF, Jankowsky ML, Eriksen EF (1996) Effects of intermittent hPTH(1–34) alone and in combination with 1, 25(OH)(2) D(3) or risedronate on endosteal bone remodeling in canine cancellous and cortical bone. J Bone Miner Res 11(5):600–613

3. Black DM, Bilezikjian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ (2005) One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 353(6):555–565

4. Masud T, Mulcahy B, Thompson AV, Donnelly S, Keen RW, Doyle DV, Spector TD (1998) Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women. Ann Rheum Dis 57(6):346–349

5. Wimalawansa SJ (1998) A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 104(3):219–226

6. Lindsay R, Cosman F, Lobo RA, Walsh BW, Harris ST, Reagan JE, Liss CL, Melton ME, Byrnes CA (1999) Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 84(9):3076–3081

7. Greenspan SL, Resnick NM, Parker RA (2003) Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 289(19):2525–2533

8. Stabnow L, Kasukawa Y, Guo R, Amaar Y, Wergedal JE, Baylink DJ, Mohan S (2002) Effect of insulin-like growth factor-1 (IGF-1) plus alendronate on bone density during puberty in IGF-1-deficient MIDI mice. Bone 30(6):909–916

9. Watts NB (2003) Bisphosphonate treatment of osteoporosis. Clin Geriatr Med 19(2):395–414

10. Shiraki M, Shiraki Y, Aoki C, Miura M (2000) Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 15(3):515–521

11. Kaneki M, Hodges SJ, Hosoi T, Fujiwara S, Lyons A, Crean SJ, Ishida N, Nakagawa M, Takechi M, Sano Y, Mizuno Y, Hoshino S, Miyao M, Inoue S, Horiki K, Shiraki M, Ouchi Y, Orimo H (2001) Japanese fermented soybean food as the major determinant of the large geographic difference in circulating levels of vitamin K2: possible implications for hip-fracture risk. Nutrition 17(4):315–321

12. Hara K, Kobayashi M, Akiyama Y (2002) Vitamin K2 (menatetrenone) inhibits bone loss induced by prednisolone partly through enhancement of bone formation in rats. Bone 31(5):575–581

13. Hara K, Akiyama Y, Nakamura T, Murota S, Morita I (1995) The inhibitory effect of vitamin K2 (menatetrenone) on bone resorption may be related to its side chain. Bone 16(2):179–184

14. Igarashi M, Yogiashi Y, Mihara M, Takada I, Kitagawa H, Kato S (2007) Vitamin K induces osteoblast differentiation through pregnane X receptor-mediated transcriptional control of the Mx2 gene. Mol Cell Biol 27(22):7947–7954

15. Iwasaki Y, Yamato H, Murayama H, Sato M, Takahashi T, Ezawa I, Kurokawa K, Fukagawa M (2003) Combination use of vitamin K2 (menatetrenone) further increases bone volume and ameliorates extremely low turnover bone induced by bisphosphonate therapy in tail-suspension rats. J Bone Miner Metab 21(3):154–160

16. Iwamoto J, Takeda T, Sato Y, Shen CL, Yeh JK (2006) Beneficial effect of pretreatment and treatment continuation with risedronate and vitamin K2 on cancellous bone loss after ovariectomy in rats: a bone histomorphometry study. J Nutr Sci Vitaminol (Tokyo) 52(5):307–315

17. Binkley N, Krueger D, Engelke J, Crenshaw T, Suttie J (2002) Vitamin K supplementation does not affect ovariectomy-induced bone loss in rats. Bone 30(6):897–900

18. Otomo H, Sakai A, Ikeda S, Tanaka S, Ito M, Phipps RJ, Nakamura T (2004) Regulation of mineral-to-matrix ratio of lumbar trabecular bone in ovariectomized rats treated with risedronate in combination with or without vitamin K2. J Bone Miner Metab 22(5):404–414

19. Polthaau L, Lespesailles E, Harba R, Jennane R, Royant V, Eynard E, Benhamou CL (1998) Fractal analysis of trabecular bone texture on radiographs: discriminant value in postmenopausal osteoporosis. Osteoporos Int 8(6):618–625

20. Laib A, Kumer JL, Majumdar S, Lane NE (2001) The temporal changes of trabecular architecture in ovariectomized rats assessed by MicroCT. Osteoporos Int 12(11):936–941

21. Lind PM, Lind L, Larsson S, Orberg J (2001) Torsional testing and peripheral quantitative computed tomography in rat humerus. Bone 29(3):265–270
22. Tarnowski CP, Ignelzi MA Jr, Wang W, Taboas JM, Goldstein SA, Morris MD (2004) Earliest mineral and matrix changes in force-induced musculoskeletal disease as revealed by Raman microspectroscopic imaging. J Bone Miner Res 19(1):64–71
23. Yerramshetty JS, Akkus O (2008) The associations between mineral crystallinity and the mechanical properties of human cortical bone. Bone 42(3):476–482
24. Hodges SJ, Akesson K, Vergnaud P, Obrant K, Delmas PD (1993) Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture. J Bone Miner Res 8(10):1241–1245
25. Kanai T, Takagi T, Masuhiro K, Nakamura M, Iwata M, Saji F (1997) Serum vitamin K level and bone mineral density in postmenopausal women. Int J Gynaecol Obstet 61(3):25–30
26. Luukinen H, Kakonen SM, Pettersson K, Koski K, Laippala P, Lovgren T, Kivela SL, Vaananen HK (2000) Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin. J Bone Miner Res 15(12):2473–2478
27. Vergnaud P, Garnero P, Meunier PJ, Breart G, Kamihagi K, Delmas PD (1997) Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab 82(3):719–724
28. Booth SL, Tucker KL, Chen H, Hannan MT, Gagnon DR, Cupples LA, Wilson PW, Ordovas J, Schaefer EJ, Wson-Hughes B, Kiel DP (2000) Dietary vitamin K intake is associated with hip fracture but not with bone mineral density in elderly men and women. Am J Clin Nutr 71(5):1201–1208
29. Feskanich D, Weber P, Willett WC, Rockett H, Booth SL, Colditz GA (1999) Vitamin K intake and hip fractures in women: a prospective study. Am J Clin Nutr 69(1):74–79
30. Hiroe M, Hashimoto J, Ando W, Ono T, Yoshikawa H (2008) Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal women. J Bone Miner Metab 26(3):260–264
31. Akiyama Y, Haru K, Ohkawa I, Tajima T (1993) Effects of menatetrenone on bone loss induced by ovariectomy in rats. Jpn J Pharmacol 62(2):145–153
32. Matsutani T, Miura H, Higaki H, Moro-Oka T, Kurata K, Murakami T, Iwamoto Y (2000) Effect of vitamin K2 on three-dimensional trabecular microarchitecture in ovariectomized rats. J Bone Miner Res 15(9):1810–1817
33. Shiraishi A, Higashi S, Masaki T, Saito M, Ito M, Ikeda S, Nakamura T (2002) A comparison of alfalcacidol and menatetrenone for the treatment of bone loss in an ovariectomized rat model of osteoporosis. Calcif Tissue Int 71(1):69–79
34. Binkley N, Krueger D, Engelke J, Sutie J (2007) Vitamin K deficiency from long-term warfarin anticoagulation does not alter skeletal status in male rhesus monkeys. J Bone Miner Res 22(5):695–700
35. Price PA (1985) Vitamin K-dependent formation of bone Gla protein (osteocalcin) and its function. Vitam Horm 42:65–108
36. Koshihara Y, Hoshi K, Ishibashi H, Shiraki M (1996) Vitamin K2 promotes 1alpha, 25(OH)2 vitamin D3-induced mineralization in human periosteal osteoblasts. Calcif Tissue Int 59(6):466–473
37. Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J, Goldstein S, Gundberg C, Bradley A, Karsenty G (1996) Increased bone formation in osteocalcin-deficient mice. Nature 382(6590):448–452
38. Ichikawa T, Horie-Inoue K, Ikeda K, Blumberg B, Inoue S (2006) Steroid and xenobiotic receptor SXR mediates vitamin K2-activated transcription of extracellular matrix-related genes and collagen accumulation in osteoblastic cells. J Biol Chem 281(25):16927–16934
39. Lim SK, Won YJ, Lee HC, Huh KB, Park YS (1999) A PCR analysis of ERalpha and ERbeta mRNA abundance in rats and the effect of ovariectomy. J Bone Miner Res 14(7):1189–1196
40. Syed FA, Modder UI, Fraser DG, Spelsberg TC, Rosen CJ, Krust A, Chambon P, Jameson JL, Khosla S (2005) Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways. J Bone Miner Res 20(11):1992–2001